Research Article

Gustatory Dysfunction among a Sample of Depressed Egyptian Adults under Antidepressants Therapy: A Retrospective Cohort Study

Christine Mikhail, Khaled Elgaaly, Ahmed Abd El Latif Abd El Hamid, Olfat Shaker, and Shereen Ali

1Oral Medicine and Periodontology Department, Faculty of Dentistry, Cairo University, Cairo, Egypt
2Oral Medicine and Periodontology Department, Faculty of Dentistry, Fayoum University, Faiyum, Egypt
3Department of Psychiatry, Faculty of Medicine, Cairo University, Cairo, Egypt
4Medical Biochemistry and Molecular Biology Department, Faculty of Medicine, Cairo University, Cairo, Egypt

Correspondence should be addressed to Christine Mikhail; dr.christine.raouf@gmail.com

Received 28 January 2021; Revised 18 February 2021; Accepted 25 February 2021; Published 4 March 2021

Academic Editor: Gaetano Isola

Copyright © 2021 Christine Mikhail et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

It is quite clear that the ability to perceive taste sensations significantly affects food choice, which consequently affects health status in the long term. Gustatory dysfunction is a neglected symptom among the depressed patients and those under antidepressants therapy, although these patients are susceptible to oral problems, due to general self-negligence related to mental disease, fear of dental treatment, and side effects of varied medications utilized in psychiatry. This study is aimed at assessing gustatory thresholds (detection and recognition thresholds) among a sample of 30 depressed Egyptian adults under antidepressants therapy for at least 3 months or psychotherapy with age ranging from 20 to 50 years old, seeking the Psychiatric Clinic at the Faculty of Medicine, Cairo University, Egypt. These patients were distributed into three equal groups (tricyclic antidepressants (TCA), selective serotonin reuptake inhibitors (SSRIs), and psychotherapy) and were assessed for gustatory detection and recognition thresholds using the filter paper disc method through a scoring system. The participants were also divided into normal taste group in which both the detection and recognition scores were 1, while the scores from 2 till 5 were considered as hypogeusia group and the score of 6 was considered as dysgeusia group. The TCA group was statistically significant from the other 2 groups in sweet detection thresholds ($p = 0.043$) and sweet recognition thresholds ($p = 0.007$). Hypogeusia for sweet was statistically significant ($p = 0.041$), where it was more common among TCA (70%) than both SSRIs and the psychotherapy group (20%). Gustatory dysfunction was found to be mostly associated with TCA followed by SSRIs particularly for sweet taste thresholds. More attention has to be given to taste changes among these patients as oral health affects general health by causing considerable pain and by changing what people eat, their speech, and their quality of life and wellbeing. Proper awareness and evaluation of this problem will improve the quality of life for the depressed patients and avoid unnecessary treatment. This trial is registered with ClinicalTrials.gov ID: NCT03599011.

1. Introduction

The depressed patients and those under antidepressants therapy are susceptible to oral problems, due to general self-negligence related to mental disease, fear of dental treatment, and side effects of varied medications utilized in psychiatry. Moreover, in recognition of a wide range of microbials, stress and damage signals, had been considered as the most important factors responsible for tissue damage linked with periodontitis [1].

In this regard, it has been hypothesized that conditions such as periodontitis and Coronary heart diseases may determine the increased release at the serum and salivary levels of IL-1, IL-6, prostaglandins, metalloproteases, NO, and hs-CRP, which, in turn, negatively influences the tone of the endothelial wall and, finally, causes a high risk of
endothelial dysfunction and CHD development [2]. Oral and periodontal diseases can determine severe functional, phonatory and aesthetic impairments and are the main cause of adult tooth loss. They are more frequent in the disadvantaged segments of society and, in particular, in subjects who have difficulty accessing preventive services and dental care [3]. Also, the relationship between taste sensation, intake behavior, and long-term health outcomes is complex, but it is quite clear that the ability to perceive taste sensations significantly affects food choice, which consequently affects health status in the long term [4].

Taste changes can be classified into hypogeusia (diminished taste sensation), dysgeusia (taste distortion), phantogeusia (phantom taste), and ageusia (taste loss) [5]. Systemic conditions and their treatments are known to influence oral health (e.g., reduced saliva flow). Saliva provides protection of hard and soft tissues; aids taste, swallowing, and digestion; and offers antimicrobial properties. Saliva contains more than two thousand proteins, enzymes, electrolytes, small organic molecules, and antimicrobials; identification and use of these salivary biomarkers is ongoing for many conditions in research such as oral/oropharyngeal cancer [6].

Taste changes are often drug related. For example, in one study, for approximately 25% of patients with taste disturbances at an ear, nose, and throat outpatient clinic, the problem was drug related [7]. 12% of olfactory dysfunction may be attributed to medication effects, and an even larger proportion of gustatory dysfunction. However, conclusive data confirming the role of medications in smell and taste disorders are few, because most evidence is based on case studies or series [8].

Data on medical variables suggested that mood disorders ranked first while anxiety disorders ranked second, 34.6 and 27.8%, respectively, followed by psychoactive substance use disorders (21.1%) and schizophrenia (6.8%). It was also suggested that 39.8% of patients had a duration of mental illness of 1–5 years, 88% of patients were independent for their daily life activities, and 65.4% of patients had no healthy practices Shah et al. [9], Shukla and Srivastava [10] suggested the reverse findings, with anxiety disorders being on top of the list and mood disorders ranking second despite the low proportion of patients (i.e., 19 and 10%). Chandu et al. [11] had similar findings; they mentioned that 45% of patients were suffering from mood disorders followed by schizophrenia (25%) and psychoactive substance use disorders (20.6%).

In circumstances such as anxiety or depression, in which serotonin (5-HT) and noradrenaline (NA) are altered, they are associated with taste disturbances, indicating the necessity of these transmitters in the determination of taste thresholds in health and disease [12]. Most of the prescribed antidepressant agents are associated with a number of significant oral complications, including sialadenitis, xerostomia, gingivitis, glossitis, stomatitis, dysgeusia, tongue edema, and discoloration, which appear almost due to salivary gland dysfunction caused by the medication [13].

It has been reported clinically that both first-generation tricyclic antidepressants (TCA) and later-developed selective serotonin reuptake inhibitors (SSRIs) cause chemosensory complaints. Despite these helpful clinical observations in determining potential chemosensory side effects of drugs, it is essential to quantify the potential taste changes by carrying out experimental studies [14]. Oral pathologies are a public health problem that has a growing prevalence that, if not properly treated, can affect the relational, psychological, and social skills of an individual [15].

The rationale of conducting such study was to determine that gustatory thresholds (detection and recognition thresholds) among a sample of depressed Egyptian adults under antidepressants therapy (TCA and SSRIs) for at least 3 months were not affected as compared to those under nonpharmacological therapy (psychotherapy), seeking the Psychiatric Clinic at the Faculty of Medicine, Cairo University, Egypt.

2. Materials and Methods

STROBE statement checklist was followed in reporting cohort studies. This trial is registered with ClinicalTrials.gov ID: NCT03599011.

The study was approved by the Ethical Committee of the Faculty of Dentistry, Cairo University (Ethical Committee Approval Number 18936). The aim of the study and its benefits were explained to each participant with emphasis on confidentiality of the collected data. Each participant signed an informed consent before being enrolled in the study.

2.1. Study Design. This is a retrospective cohort study.

2.2. Setting. The subjects had been recruited from the Psychiatric Clinic at the Faculty of Medicine, Cairo University, Egypt.

2.3. Participants. A sample of 30 depressed patients under antidepressants therapy for at least 3 months or psychotherapy, with age ranging from 20 to 50 years old, seeking the Psychiatric Clinic at the Faculty of Medicine, Cairo University, was recruited during a period of almost 7 months starting from February 2020 to August 2020. Those who were of ages other than the mentioned, or under antipsychotics, hypnotics, or anticonvulsants therapies or suffered from olfactory dysfunction, were excluded.

The thirty eligible patients were recalled using their phone numbers recorded in their follow-up records, were asked to come to the Diagnosis Center at the Faculty of Dentistry, Cairo University, in order to be assessed for gustatory functions and were given identification numbers and distributed into three equal groups (Exposure 1: TCA; Exposure 2: SSRIs; and non-Exposure: psychotherapy), to which the operator was blinded to avoid selection bias. Nonrespondent bias was minimized by explaining to the participants the aim of the study and their importance and role in the study.
2.4. Variables and Data Sources/Measurement

2.4.1. Outcomes. The gustatory thresholds were assessed using filter paper disc method in which test discs were placed on the tongue (Nagai et al. [16]). The gustatory tests were carried out in the morning during fasting state using five concentrations of the substances to test the four tastes: sweet, salty, sour, and bitter. Five concentrations of each of the four tastes were only used, as, practically, one should be cautious that subjects undergo sensory fatigability which causes limitations to the number of tests that can be done. So, when determining recognition thresholds, a number of five or six different compounds is the maximum recommendation to be investigated [17].

Test discs of 5 mm in diameter were wetted with a solution and placed on the left lateral part of the tongue at approximately 2 cm from the proglottis (the tip of the tongue), which is thought to be innervated by the chorda tympani nerve. During the tests, the participants were instructed to rinse their mouths with distilled water before testing the next concentration. A one-minute interval after water rinses is necessary before presenting further solutions.

The five concentrations of the four tastes (sweet, salty, sour, and bitter) used were starting from the lowest concentration then ascending to the highest possible concentration of each taste as follows: sweet—0.8 M, 1.2 M, 1.4 M, 1.6 M, and 2 M; salty—0.02 M, 0.1 M, 0.2 M, 0.3 M, and 1.2 M; sour—0.01 M, 0.02 M, 0.06 M, 0.1 M, and 1.2 M; and bitter—0.04 M, 0.15 M, 0.3 M, 0.6 M, and 0.9 M.

The concentrations of each taste were serially scored from disc number 1 (lowest) to number 5 (highest). If the subject was not able to recognize the taste at the highest concentration, a score of 6 was given. The detection threshold was defined as the concentration at which the subjects clearly identified the quality of the taste, while the recognition threshold was defined as the solution at which the subjects clearly identified the quality of the taste. The participants were also divided into normal taste group in which both the detection and the recognition scores were 1, while scores from 2 till 5 were considered as hypogeusia group and a score of 6 was considered as dysgeusia group.

2.4.2. Exposures

E1: Exposure 1—commonly prescribed tricyclic antidepressants (imipramine, amitriptyline, and clomipramine HCL)

E2: Exposure 2—commonly prescribed selective serotonin reuptake inhibitors antidepressants (fluoxetine, fluvoxamine, sertraline, citalopram, and paroxetine)

2.4.3. Nonexposure. This includes nonpharmacological treatment (psychotherapy).

2.4.4. Predictors. Age ranged from 20 to 50 years old. Gender was assessed as male or female. Social level was assessed by residence in urban or rural areas. Time since starting antidepressants therapy: at least 3 months ago. Presence of complications associated with antidepressants therapy: gustatory dysfunction (taste changes) was assessed by taste intensity measurements.

2.4.5. Effect Modifiers. The participant’s mouth was rinsed with distilled water before testing the next concentration to avoid the affection of taste intensity measurements by the presence of residual stimuli from prior testing (Zverev [18]).

2.4.6. Potential Confounders. It was quite clear that the ability to perceive taste sensations significantly affected food choice, which consequently affected health status in the long term (Snyder and Bartoshuk [4]).

2.4.7. Bias. The eligible patients were recalled, given identification numbers and divided into three groups, to which the operator was blinded to avoid selection bias. Nonrespondent bias was minimized by explaining to the participants the aim of the study, their importance, and role in the study. Incomplete records were excluded from statistical analysis with reporting the cause of not completing the record.

2.4.8. Sample Size. Based on the previous paper by Ramzy [19], taste disturbances were found in 8% in SSRIs and 83% in tricyclic group. Using power 95% and 5% significance level, 8 patients in each group were required. Sample size was calculated by PS program.

2.4.9. Statistical Methods. All the results were subjected to statistical analysis. Data management and statistical analysis were performed using the Statistical Package for Social Sciences (SPSS) version 25. Numerical data were summarized using means and standard deviations and ranges. Categorical data were summarized as percentages. Data were explored for normality using Kolmogorov–Smirnov test and Shapiro–Wilk test. Comparisons between the 3 groups with respect to numeric variables were done using the one-way ANOVA. Pairwise differences were detected by Bonferroni’s post hoc test. For categorical variables, differences were analyzed with chi square ($\chi^2$) test and Fisher’s exact test when appropriate. Adjustments of $p$ value were done using the Bonferroni method for multiple testing. All $p$ values are two-sided. $p$ values ≤ 0.05 were considered statistically significant.

3. Results

From 30 enrolled patients, 30 patients were included in the study. The flowchart of the patients through the study following the CONSORT flow diagram is presented in Figure 1. Regarding basic parameters of the studied groups (Table 1), there was no significant difference.

As for the psychiatric disorders which the participants were diagnosed with (Table 1), there was no significant difference between groups for depression alone and...
depression with other psychiatric problems as obsessive compulsive disorder (OCD) and generalized anxiety disorder (GAD) \( p = 0.510 \). Regarding the medical history of the patients, there was no significant difference between groups for systemic diseases \( p = 0.531 \) and medications other than antidepressants \( p = 1.000 \). Concerning the dental history of the patients, there was no significant difference between groups for oral hygiene status \( p = 0.531 \) and dental care frequency \( p = 0.406 \).

The results of the present study revealed that the mean score for sweet detection threshold was 1.4 ± 0.7, 1 ± 0, 1 ± 0 for TCA, SSRI, and psychotherapy, respectively. This was statistically significant \( p = 0.043 \). The mean score for sweet detection threshold concentration was 0.9 ± 0.2, 0.8 ± 0, and 0.8 ± 0 for TCA, SSRIs, and psychotherapy, respectively. This was statistically significant \( p = 0.040 \). The mean score for recognition threshold of sweet taste was 2.1 ± 1.0, 1.2 ± 0.4, and 1.2 ± 0.4 for TCA, SSRIs, and psychotherapy, respectively. This was statistically significant \( p = 0.007 \). The mean score for recognition threshold of sweet taste concentration was 1.2 ± 0.3, 0.9 ± 0.2, and 0.9 ± 0.2 for TCA, SSRIs, and psychotherapy, respectively. This was statistically significant \( p = 0.008 \); pairwise comparisons revealed that TCA group was statistically significant from the other 2 groups in sweet taste thresholds (Table 2).

However, in the present study, the mean scores for salt detection threshold \( p = 0.220 \), salt detection threshold concentration \( p = 0.247 \), recognition threshold of salt taste \( p = 0.121 \), and recognition threshold of salt taste concentration \( p = 0.129 \) for TCA, SSRIs, and psychotherapy groups were statistically not significant (Table 3). Also, the mean scores for sour detection threshold \( p = 0.680 \), sour detection threshold concentration \( p = 0.572 \), recognition threshold of sour taste \( p = 0.880 \), and recognition threshold of sour taste concentration \( p = 0.073 \) for TCA, SSRIs, and psychotherapy were statistically not significant (Table 4). Similarly, the mean scores for bitter detection threshold \( p = 0.284 \), bitter detection threshold concentration \( p = 0.246 \), recognition threshold of bitter taste \( p = 0.286 \), and recognition threshold of bitter taste concentration \( p = 0.358 \) for TCA, SSRIs, and psychotherapy groups were statistically not significant (Table 5). These findings indicated that regarding the four taste qualities thresholds, TCA group differed from the other two groups mainly in sweet taste thresholds.

Regarding taste abnormalities between groups, the significant difference was detected in the detection of phantogeusia. 70% of psychotherapy group reported phantogeusia, in contrast to only 20% in TCA and SSRIs groups as shown in (Figure 2).

Hypogeusia for sweet was statistically significant \( p = 0.041 \); 70% of TCA patients suffered from hypogeusia while 20% in SSRI and Psychotherapy group as shown in Figure 3. Abnormalities for other tastes were comparable between groups.

4. Discussion

The results of the present study revealed that the mean score for sweet detection threshold was 1.4 ± 0.7, 1 ± 0, 1 ± 0 for TCA, SSRI, and psychotherapy, respectively. This was
Table 1: Descriptive statistics, one-way ANOVA, Chi square tests, and Fisher’s exact test for the demographic data and other variables of the tested groups.

| Variables                  | TCA (n = 10) | SSRIs (n = 10) | Psychotherapy (n = 10) | P value |
|----------------------------|--------------|----------------|------------------------|---------|
| Age (yrs.)                 | Mean ± SD    | No.  %         | No.  %                  | 0.072   |
|                            | Range        |                |                        |         |
|                            | 38.6 ± 7.6   | 80.0 6 40.0    | 80.0 6 40.0             |         |
|                            | 24–50        |                | 22–47                  |         |
| Sex                       | Male         | 2 20.0        | 2 20.0                  | 0.668   |
|                           | Female       | 8 80.0        | 6 60.0                  |         |
| Weight (kg)                | Mean ± SD    | No.  %         | No.  %                  | 0.087   |
|                            | Range        |                |                        |         |
|                            | 78.1 ± 7.8   | 80.0 6 40.0    | 80.0 6 40.0             |         |
|                            | 65–90        |                | 45–100                  |         |
| Residence                  | Rural        | 2 20.0        | 4 40.0                  | 0.082   |
|                           | Urban        | 8 80.0        | 6 60.0                  |         |
| Marital status             | Divorced     | 0 0.0         | 0 0.0                   | NA      |
|                           | Married      | 3 30.0        | 5 50.0                  | 0.527   |
|                           | Single       | 5 50.0        | 5 50.0                  |         |
|                           | Widow        | 2 20.0        | 0 0.0                   |         |
| Marital status             | Married      | 3 30.0        | 5 50.0                  | 0.50    |
|                           | Single       | 5 50.0        | 5 50.0                  |         |
|                           | Widow        | 2 20.0        | 0 0.0                   |         |
| Education                  | Basic/no education | 4 40.0 6 50.0 | 0 0.0                  | 0.073   |
|                           | Secondary/high school | 2 20.0 3 30.0 | 3 30.0    |         |
|                           | University degree | 4 40.0 2 20.0 | 7 70.0    |         |
| Work status                | Not working  | 6 60.0        | 6 60.0                  | 0.698   |
|                           | Working      | 4 40.0        | 3 30.0                  |         |
|                           | Yes          | 1 10.0        | 3 30.0                  |         |
| Depression comorbid        | Depression alone | 8 80.0 6 50.0 | 5 50.0    | 0.51    |
|                           | With other psychiatric problems | 2 20.0 4 50.0 | 2 20.0    |         |
| Systemic diseases          | No           | 7 70.0        | 4 40.0                  | 0.531   |
|                           | Yes          | 3 30.0        | 6 60.0                  |         |
| Medication                 | No           | 6 60.0        | 5 50.0                  | 1.000   |
|                           | Yes          | 4 40.0        | 5 50.0                  |         |
| Oral hygiene status        | Bad          | 7 70.0        | 6 60.0                  | 0.531   |
|                           | Good-moderate| 3 30.0        | 4 60.0                  |         |
| Dental care frequency      | Irregular    | 3 30.0        | 5 50.0                  | 0.406   |
|                           | Regular      | 0 0.0         | 1 10.0                  |         |
|                           | Symptomatic  | 7 70.0        | 4 60.0                  |         |

Table 2: Descriptive statistics and one-way ANOVA for sweet detection and recognition thresholds scores and concentrations among the tested groups.

| Variables                  | Mean | SD | 95% CI Lower | 95% CI Upper | Min. | Max. | p value |
|----------------------------|------|----|--------------|--------------|------|------|---------|
| Sweet detection threshold score | TCA* | 1.4 | 0.7 | 0.9 | 1.9 | 1.0 | 3.0 | 0.043 |
|                            | SSRIs | 1.0 | 0.0 | 1.0 | 1.0 | 1.0 | 1.0 |      |
|                            | Psychotherapy | 1.0 | 0.0 | 1.0 | 1.0 | 1.0 | 1.0 |      |
| Sweet detection threshold conc | TCA* | 0.9 | 0.2 | 0.8 | 1.1 | 0.8 | 1.4 | 0.040 |
|                            | SSRIs | 0.8 | 0.0 | 0.8 | 0.8 | 0.8 | 0.8 |      |
|                            | Psychotherapy | 0.8 | 0.0 | 0.8 | 0.8 | 0.8 | 0.8 |      |
| Sweet recognition threshold score | TCA* | 2.1 | 1.0 | 1.4 | 2.8 | 1.0 | 4.0 | 0.007 |
|                            | SSRIs | 1.2 | 0.4 | 0.9 | 1.5 | 1.0 | 2.0 |      |
|                            | Psychotherapy | 1.2 | 0.4 | 0.9 | 1.5 | 1.0 | 2.0 |      |
| Sweet recognition threshold conc | TCA* | 1.2 | 0.3 | 1.0 | 1.4 | 0.8 | 1.6 | 0.008 |
|                            | SSRIs | 0.9 | 0.2 | 0.8 | 1.0 | 0.8 | 1.2 |      |
|                            | Psychotherapy | 0.9 | 0.2 | 0.8 | 1.0 | 0.8 | 1.2 |      |
|                            | SSRIs | 3.7 | 2.1 | 2.2 | 5.2 | 1.0 | 6.0 |      |
|                            | Psychotherapy | 5.1 | 1.7 | 3.9 | 6.3 | 2.0 | 6.0 |      |
statistically significant ($p = 0.043$). The mean score for sweet detection threshold concentration was $0.9 \pm 0.2$, $0.8 \pm 0$, and $0.8 \pm 0$ for TCA, SSRIs, and psychotherapy, respectively. This was statistically significant ($p = 0.040$). The mean score for recognition threshold of sweet taste was $2.1 \pm 1.0$, $1.2 \pm 0.4$, and $1.2 \pm 0.4$ for TCA, SSRIs, and psychotherapy, respectively.
respectively. This was statistically significant ($p = 0.007$). The mean score for recognition threshold of sweet taste concentration was $1.2 \pm 0.3$, $0.9 \pm 0.2$, and $0.9 \pm 0.2$ for TCA, SSRIs, and psychotherapy, respectively. This was statistically significant ($p = 0.008$); pairwise comparisons revealed that TCA group was statistically significant from the other 2 groups in sweet taste thresholds.

However, in the present study, the mean scores for salt detection threshold ($p = 0.220$), salt detection threshold concentration ($p = 0.247$), recognition threshold of salt taste ($p = 0.121$), and recognition threshold of salt taste concentration ($p = 0.129$) for TCA, SSRIs, and psychotherapy groups were statistically not significant. Also, the mean scores for sour detection threshold ($p = 0.680$), sour detection threshold concentration ($p = 0.572$), recognition threshold of sour taste ($p = 0.880$), and recognition threshold of sour taste concentration ($p = 0.073$) for TCA, SSRIs, and psychotherapy were statistically not significant (Table 4). Similarly, the mean scores for bitter detection threshold ($p = 0.284$), bitter detection threshold concentration ($p = 0.246$), recognition threshold of bitter taste ($p = 0.286$), and recognition threshold of bitter taste concentration ($p = 0.358$) for TCA, SSRIs, and psychotherapy groups were statistically not significant. These findings indicated that regarding the four taste qualities thresholds, TCA group differed from the other two groups mainly in sweet taste thresholds.

Regarding taste abnormalities between groups, the significant difference was detected in the detection of phantogeusia. 70% of psychotherapy group reported phantogeusia, in contrast to only 20% in TCA and SSRIs groups. Hypogeusia for sweet was statistically significant ($p = 0.041$); 70% of TCA patients suffered from hypogeusia while 20% in SSRI and Psychotherapy group. Abnormalities for other tastes were comparable between groups.

The results of the present study showed that TCA group was statistically significant from the other 2 groups in sweet detection thresholds scores ($p = 0.043$) and concentrations ($p = 0.040$) and also sweet recognition thresholds scores ($p = 0.007$) and concentrations ($p = 0.008$). This significance
could partially be in agreement with Kampov-Polevoy et al. [20, 21] who mentioned that cravings for sweet foods and increased hedonic responses to sweet tastes are described among patients with psychiatric disorders, particularly seasonal affective disorder.

In comparison with previous studies of responses to sweet tastes in Major Depressive Disorders (MDD), Berlin et al. [22] mentioned increased sweet taste thresholds but equivalent hedonic responses to sucrose in adults with and without MDD. Kazes et al. [23] mentioned a preference for sweet foods in MDD that was not changed with antidepressant therapy, but responses to varying concentrations of sweet solutions were not officially assessed, in which the present study was partially in contrast with it.

However, there was a contradiction to the above mentioned studies and the present study in a study by Dichter et al. [24] to examine responses to sweet tastes via the Sweet Taste Test (STT [25]) in adult outpatients with MDD before and after psychotherapy and compared response profiles to those of nondepressed control participants also examined at two points in time, in which they reported that there were no significant differences in STT response profiles between groups overall or at either time point and did not differ after psychotherapy, relative to baseline. These findings suggested that although anhedonia may be a symptom of MDD, the disorder was not characterized by altered responses to sweet tastes.

Concerning SSRIs group in the present study, clinical reports mentioned that some patients associate SSRIs treatment with an experience of emotional blunting through which emotional responses to both aversive and pleasurable experiences are decreased [26, 27]. Experimental studies in animals and humans indicated that serotonin pathways exhibited an inhibitory impact over neural systems mediating both positive and negative affective processes [28]. Thus, increasing the serotonin function by SSRIs would produce a form of “emotional constraint” in which the salience of both rewarding and aversive stimuli is lost [28]. These findings could be in partial agreement with the present study where TCA group was found to be statistically significant from SSRIs group in sweet taste detection and recognition thresholds, but it could not be denied that there were still greater sweet taste thresholds among SSRIs group which meant that the salience of rewarding was not lost completely. However, evaluating the effect of SSRIs on emotional responses in depressed patients is difficult as modest degrees of emotional blunting might be difficult for individuals to detect or report subjectively [29].

Considering TCA group, it was found to be statistically significant from the other 2 groups in sweet taste thresholds in the present study. This finding was in agreement with Maddox et al. [30] who reported that the taste side effects of tricyclic antidepressants reported would contribute to the discontinuation rates reported in studies of depressed patients. It was also concluded that the discontinuation rate due to side effects was higher for tricyclic antidepressants than for selective serotonin reuptake inhibitors by Anderson and Tomenson and Martin et al. [31, 32].

Moreover, in a randomized controlled study by Ramzy [19], the combined use of pregabalin plus paroxetine (SSRRI) for fibromyalgia management in comparison with the combined use of pregabalin plus either amitriptyline (TCA) or venlafaxine was evaluated. Medication termination due to drowsiness, dizziness, blurred vision, abnormal taste, hunger, hallucination, urination problems, and sexual dysfunction was reported mostly in the amitriptyline group. It was concluded that the combined use of pregabalin plus paroxetine provides an effective method with increased tolerability to decrease the somatic and depressive symptoms of fibromyalgia and to improve the quality of life in affected individuals. These findings supported that TCA had more taste side effects and less tolerability than SSRIs which supported the revealed result of the present study concerning TCA group being statistically significant from the other 2 groups in sweet taste thresholds.

However, in the present study, the mean scores for salt detection threshold, salt detection threshold concentration, recognition threshold of salt taste, and recognition threshold of salt taste concentration for TCA, SSRIs, and psychotherapy groups were statistically not significant (p = 0.220), (p = 0.247), (p = 0.121), and (p = 0.129), respectively. Also, the mean scores for sour detection threshold, sour detection threshold concentration, recognition threshold of sour taste and recognition threshold of sour taste concentration for TCA, SSRIs, and Psychotherapy were statistically not significant (p = 0.680), (p = 0.572), (p = 0.880), and (p = 0.073), respectively. Similarly, the mean scores for bitter detection threshold, bitter detection threshold concentration, recognition threshold of bitter taste, and recognition threshold of bitter taste concentration for TCA, SSRIs, and psychotherapy groups were statistically not significant (p = 0.284), (p = 0.246), (p = 0.286), and (p = 0.358), respectively. These findings indicated that regarding the four taste qualities taste thresholds, that the most affected taste is sweet taste thresholds and TCA group differed from the other two groups particularly in sweet taste thresholds. These findings were in contrast to a study performed by Schiffman et al. [33], who reported that intermittent application of the tricyclic antidepressant amitriptyline HCl led to taste decrements only for salts, while continuous application affected all of the taste qualities to varying degrees.

Considering studies performed on depressive patients, it would be essential to separate the possible effect of depressive status on taste responses from systemic use of antidepressant medications as it has been known that depressive symptomatology affects scores on cognitive measures, and emotional factors may impact sensory/perceptual responses also. Therefore, the present study included a non-exposure group which included depressed patients under nonpharmacological therapy.

The present study revealed a significant difference between groups that was detected in phantogeusia (p = 0.041), where 70% of psychotherapy group reported phantogeusia, while only 20% in TCA and SSRIs groups which is considered in agreement with Dess and Edelheit [34] who found that subjects would particularly rate stimuli as more bitter if
they were placed under stress or [35] scored higher on subclinical depression scores.

Moreover, clinical reports mentioned that antidepressant drugs could cause taste disturbances including dysgeusia (distortion of taste), hypogeusia (diminished sensitivity of taste), and ageusia (absence of taste) [36] which is in acceptance with the present study which revealed that hypogeusia for sweet was statistically significant ($p = 0.041$), where 70% of TCA patients had hypogeusia while only 20% in both SSRI and psychotherapy groups. This is also in agreement with Schiffman et al. [14] who reported that both first-generation tricyclic antidepressants and later-developed selective serotonin reuptake inhibitors are mentioned clinically to cause chemosensory complaints. However, McClain et al. [37] reported that hypogeusia is common in acutely ill patients and those recovering from prolonged illness. It is an incidental finding as patients generally do not complain of it. It is only discovered in discussions on condiments of food or salt intake. A number of diseases such as rheumatoid arthritis, Crohn’s disease, trauma, stress, and thermal injury that lead to marked losses of zinc, resulting in hypogeusia.

The oral health should not be separated from the remainder of the body as it affects general health by causing considerable pain and by changing what people eat, their speech, and their quality of life and well-being. Gustatory dysfunction should not be neglected in depressed patients and those under antidepressants therapy. It should be considered as a real pathophysiological symptom in depressed patients, and more work should be done on the mechanisms through which gustatory function is disturbed in depression. More experimental studies should be done to essentially quantify potential taste changes among patients under antidepressants therapy.

Health care providers should know the causes of taste disorders in order to be capable of reaching correct diagnosis and planning treatment without unnecessary dental treatment. It should be noted that before taste changes assessment for any causes, dental causes should be first ruled out and the diagnosis of a gustatory dysfunction must be supported with a thorough medical history, the patient’s subjective reporting, and psychophysical testing.

5. Conclusions

The results of the present study can conclude that gustatory dysfunction is a neglected system among the depressed patients and those under antidepressants therapy till now, where gustatory dysfunction was found to be mostly associated with TCA followed by SSRIs and the depressed patients undergoing psychotherapy particularly for sweet taste thresholds. Moreover, phantogeusia was common among depressed patients undergoing psychotherapy while hypogeusia for sweet was more common among TCA than SSRIs. More attention has to be given to taste changes among these patients as oral health affects general health by causing considerable pain and by changing what people eat, their speech, and their quality of life and wellbeing. Proper awareness and evaluation of this problem will reduce its impact and improve the quality of life for the depressed patients.

Data Availability

The data used to support the findings of this study are included within the article.

Conflicts of Interest

The authors declare that they have no conflicts of interest regarding the publication of this paper.

Acknowledgments

The authors thank all the staff members of Oral Medicine, Periodontology, and Diagnosis Department, Faculty of Dentistry, Cairo University, and Fayoum University and also all the staff members of Psychiatric Department and Clinic, Faculty of Medicine, Cairo University, for their cooperation and support. This study was self-funded by the authors.

References

[1] G. Isola, A. Lo Giudice, A. Polizzi, A. Alibrandi, P. Murabito, and F. Indelicato, “Identification of the different salivary Interleukin-6 profiles in patients with periodontitis: a cross-sectional study,” Archives of Oral Biology, vol. 122, p. 104997, 2021.
[2] G. Isola, A. Polizzi, A. Alibrandi, R. C. Williams, and R. Leonardi, “Independent impact of periodontitis and cardiovascular disease on elevated soluble urokinase-type plasminogen activator receptor (suPAR) levels,” Journal of Periodontology, pp. 1–11, 2020.
[3] G. Isola, “The impact of diet, nutrition and nutraceuticals on oral and periodontal health,” Nutrients, vol. 12, no. 9, pp. 2724–2726, 2020.
[4] D. J. Snyder and L. M. Bartoshuk, “Epidemiological studies of taste function,” Annals of the New York Academy of Sciences, vol. 1170, pp. 1–9, 2009.
[5] N. Su, V. Ching, and M. Grushka, “Taste disorders: a review,” Journal of the Canadian Dental Association, vol. 79, 2013.
[6] G. Isola, “Advances in biomarkers and diagnostics in periodontitis and oral diseases,” International Journal of Environmental Research and Public Health, vol. 18, 2021.
[7] H. Tomita and T. Yoshikawa, “Drug-related taste disturbances,” Acta Oto-Laryngologica. Suplementum, vol. 546, 2002.
[8] J. Malaty and I. A. C. Malaty, “Smell and taste disorders in primary care,” American Family Physician, vol. 15, 2013.
[9] V. Shah, N. Patel, and P. Jain, “Oral health of psychiatric patients: a cross-sectional comparison study,” Dental Research Journal, vol. 9, no. 2, p. 209, 2012.
[10] G. D. Shukla and R. P. Srivastava, “A psychiatric study of cases attending dental o.p.d of a teaching general hospital,” Indian Journal of Psychiatry, vol. 25, no. 3, pp. 198–202, 1983.
[11] G. Chandu, M. Shafulia, and M. Kumar, “Oral health status and treatment needs in institutionalized psychiatric patients: one year descriptive cross sectional study,” Indian Journal of Dental Research, vol. 17, no. 4, p. 171, 2006.
[12] T. P. Heath, J. K. Melichar, D. J. Nutt, and L. F. Donaldson, “Human taste thresholds are modulated by serotonin and noradrenaline,” Journal of Neuroscience, vol. 26, no. 49, pp. 12664–12671, 2006.
[13] P. D. V. de Ameida, A. C. B. R. Johann, L. R. de Azevedo Alanis, and A. M. T. Grégio, “Antidepressants: side effects in the
mouth,” in Oral Health Care-Pediatric, Research, Epidemiology and Clinical Practices, pp. 113–128, Universidade Federal do Paraná, Curitiba, Brazil, 2012, http://cdn.intechopen.com/pdfs/29338/InTech-Antidepressants_side_effects_in_the_mouth.pdf.

[14] S. S. Schiffman, J. Zervakis, M. S. Suggs, K. C. Budd, and L. Iuga, “Effect of tricyclic antidepressants on taste responses in humans and gerbils,” Pharmacology Biochemistry and Behavior, vol. 65, no. 4, pp. 599–609, 2000.

[15] G. Isola, “Oral health and related factors associated with general health and quality of life,” Applied Sciences, vol. 10, no. 13, p. 4663, 2020.

[16] A. Nagai, M. Kubota, Y. Katayama, and C. Kojima, “Evaluation of taste acuity by the filter-paper disc in Japanese young women: the relationship with micronutrients status,” Asia Pacific Journal of Clinical Nutrition, vol. 21, no. 3, pp. 406–410, 2012.

[17] R. M. Pangborn, “Influence of hunger on sweetness preferences and taste thresholds,” The American Journal of Clinical Nutrition, vol. 7, no. 3, pp. 280–287, 1959.

[18] Y. P. Zverev, “Effects of caloric deprivation and satiety on sensitivity of the gustatory system,” BMC Neuroscience, vol. 5., 2004.

[19] E. A. Ramzy, “Comparative efficacy of newer antidepressants in combination with pregabalin for fibromyalgia syndrome: a controlled, randomized study,” Pain Practice, vol. 17, no. 1, pp. 32–40, 2017.

[20] A. B. Kampov-Polevoy, D. Ziedonis, M. L. Steinberg et al., “Association between sweet preference and paternal history of alcoholism in psychiatric and substance abuse patients,” Alcoholism: Clinical & Experimental Research, vol. 27, no. 12, p. 1929, 2003.

[21] A. B. Kampov-Polevoy, C. Eick, G. Boland, E. Khalitov, and A. Puech, “Measures of anhedonia and hedonic responses to sucrose in depressive and schizophrenic patients in comparison with healthy subjects,” European Psychiatry, vol. 13, no. 6, pp. 303–309, 1998.

[22] M. Kazes, J. M. Danion, D. Grangé et al., “Eating behaviour and depression before and after antidepressant treatment: a prospective, naturalistic study,” Journal of Affective Disorders, vol. 30, no. 3, pp. 193–207, 1994.

[23] G. S. Dichter, M. J. Smoski, A. B. Kampov-Polevoy, R. Gallop, and J. C. Garbutt, “Unipolar depression does not moderate responses to the sweet taste test,” Depression and Anxiety, vol. 27, no. 9, pp. 859–863, 2010.

[24] A. B. Kampov-Polevoy, A. Alterman, E. Khalitov, and J. C. Garbutt, “Sweet preference predicts mood altering effect of and impaired control over eating sweet foods,” Eating Behaviors, vol. 7, no. 3, pp. 181–187, 2006.

[25] J. Price, V. Cole, and G. M. Goodwin, “Emotional side-effects of selective serotonin reuptake inhibitors: qualitative study,” British Journal of Psychiatry, vol. 195, no. 3, pp. 211–217, 2009.

[26] A. Opbroek, P. L. Delgado, C. Laukes et al., “Emotional blunting associated with SSRI-induced sexual dysfunction. Do SSRIs inhibit emotional responses?” The International Journal of Neuropsychopharmacology, vol. 5, no. 2, pp. 147–151, 2002.

[27] D. H. Zald and R. A. Depue, “Serotonergic functioning correlates with positive and negative affect in psychiatrically healthy males,” Personality and Individual Differences, vol. 30, no. 1, pp. 71–86, 2001.

[28] C. McCabe, Z. Mishor, P. J. Cowen, and C. J. Harmer, “Diminished neural processing of aversive and rewarding stimuli during selective serotonin reuptake inhibitor treatment,” Biological Psychiatry, vol. 67, no. 5, pp. 439–445, 2010.

[29] J. C. Maddox, M. Levi, and C. Thompson, “The compliance with antidepressants in general practice,” Journal of Psychopharmacology, vol. 8, no. 1, pp. 48–52, 1994.

[30] I. M. Anderson and B. M. Tomenson, “Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: a Meta-analysis,” BMJ, vol. 310, no. 6992, pp. 1433–1435, 1995.

[31] R. M. Martin, S. R. Hilton, S. M. Kerry, and N. M. Richards, “General practitioners’ perceptions of the tolerability of antidepressant drugs: a comparison of selective serotonin reuptake inhibitors and tricyclic antidepressants,” BMJ, vol. 314, no. 7081, p. 646, 1997.

[32] S. S. Schiffman, J. Zervakis, M. S. Suggs, E. Shaio, and E. A. Sattely-Miller, “Effect of medications on taste,” Physiology & Behavior, vol. 66, no. 2, pp. 193–199, 1999.

[33] N. K. Dess and D. Edelheit, “The bitter with the sweet: the taste/stress/temperament nexus,” Biological Psychology, vol. 48, no. 2, pp. 103–119, 1998.

[34] N. K. Dess and C. D. Chapman, “Individual differences in taste, body weight, and depression in the "helplessness" rat model and in humans,” Brain Research Bulletin, vol. 24, no. 5, pp. 669–676, 1990.

[35] F. H. Epstein and S. S. Schiffman, “Taste and smell in disease,” New England Journal of Medicine, vol. 308, no. 21, pp. 1275–1279, 1983.

[36] C. J. McClain, M. L. McClain, M. G. Boosalis, and B. Hennig, “Zinc and the stress response,” Scandinavian Journal of Work, Environment and Health, vol. 19, pp. 132–133, 1993.